4.6 Article

Predictors of weight loss in patients with obesity treated with a Very Low-Calorie Ketogenic Diet

Journal

FRONTIERS IN NUTRITION
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnut.2023.1058364

Keywords

fibroblast growth factor 21; insulin resistance; body composition; low carbohydrate diet (LCD); very low energy diet; protein sparing modified fasting

Ask authors/readers for more resources

The Very Low-Calorie Ketogenic Diet (VLCKD) is a safe and effective intervention for metabolic diseases and obesity. This study examined the predictors of weight loss during VLCKD treatment, including the role of Fibroblast Growth Factor 21 (FGF21). Results revealed that VLCKD led to improvements in body weight, composition, and metabolic parameters. Lower baseline FGF21, male sex, and central obesity were associated with greater weight loss. This suggests that individuals with these characteristics may benefit more from VLCKD in terms of weight loss. More research is needed to determine if these findings are specific to VLCKD or apply to other calorie restriction diets.
Introduction: The Very Low-Calorie Ketogenic Diet (VLCKD) has emerged as a safe and effective intervention for the management of metabolic disease. Studies examining weight loss predictors are scarce and none has investigated such factors upon VLCKD treatment. Among the molecules involved in energy homeostasis and, more specifically, in metabolic changes induced by ketogenic diets, Fibroblast Growth Factor 21 (FGF21) is a hepatokine with physiology that is still unclear. Methods: We evaluated the impact of a VLCKD on weight loss and metabolic parameters and assessed weight loss predictors, including FGF21. VLCKD is a severely restricted diet (<800 Kcal/die), characterized by a very low carbohydrate intake (<50 g/day), 1.2-1.5 g protein/kg of ideal body weight and 15-30 g of fat/day. We treated 34 patients with obesity with a VLCKD for 45 days. Anthropometric parameters, body composition, and blood and urine chemistry were measured before and after treatment. Results: We found a significant improvement in body weight and composition and most metabolic parameters. Circulating FGF21 decreased significantly after the VLCKD [194.0 (137.6-284.6) to 167.8 (90.9-281.5) p < 0.001] and greater weight loss was predicted by lower baseline FGF21 (Beta = -0.410; p = 0.012), male sex (Beta = 0.472; p = 0.011), and central obesity (Beta = 0.481; p = 0.005). Discussion: VLCKD is a safe and effective treatment for obesity and obesity related metabolic derangements. Men with central obesity and lower circulating FGF21 may benefit more than others in terms of weight loss obtained following this diet. Further studies investigating whether this is specific to this diet or to any caloric restriction are warranted.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available